BEATcc / ENGOT-Cx10 / GOG-3030
A second immunotherapy confirmed that adding a checkpoint inhibitor to chemotherapy plus bevacizumab extends life in advanced cervical cancer.
PFS 13.7 vs 10.4 months (HR 0.62) and OS 32.1 vs 22.8 months (HR 0.68; Lancet 2024), the longest median survival reported in this setting, with benefit irrespective of PD-L1. Regulatory approval status differs by region; check the current label.
Setting
Metastatic, persistent, or recurrent cervical cancer, first line: atezolizumab + cisplatin/carboplatin-paclitaxel + bevacizumab vs the same without atezolizumab
Phase
Phase 3
Sponsor
GEICO / Roche
Registry
Headline result
OS 32.1 vs 22.8 months (HR 0.68).
Reported
2023
Enrolled
410
In plain words
What these results mean for people, not percentages
Progression-free survivalprimarysurrogate endpoint
- Median 13.7 vs 10.4 months with Atezolizumab + chemo + bev compared with Chemo + bev; about 3.3 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 38 percent lower chance of the event at any given time (hazard ratio 0.62, likely range 0.49 to 0.78).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
Overall survivalprimarysurvival endpoint
- Median 32.1 vs 22.8 months with Atezolizumab + chemo + bev compared with Chemo + bev; about 9.3 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 32 percent lower chance of the event at any given time (hazard ratio 0.68, likely range 0.52 to 0.88).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
Be careful
- These results apply to the people the trial enrolled: Metastatic, persistent, or recurrent cervical cancer, first line: atezolizumab + cisplatin/carboplatin-paclitaxel + bevacizumab vs the same without atezolizumab. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
410 participants enrolled.
Progression-free survivalprimary
HR 0.62 (0.49–0.78)
Atezolizumab + chemo + bev
13.7 mo
Chemo + bev
10.4 mo
cancers
1targets
2drugs
4ApprovedMonoclonal antibody (anti-PD-L1)
Atezolizumab · Tecentriq / Tecentriq Hybreza (SC)
ApprovedMonoclonal antibody (anti-VEGF)
Bevacizumab · Avastin (and biosimilars)
ApprovedCytotoxic chemotherapy (platinum)
Cisplatin · Platinol (generic)
ApprovedCytotoxic chemotherapy (taxane)
Paclitaxel / nab-paclitaxel · Taxol / Abraxane